Page last updated: 2024-10-23

benserazide and Psychotic Disorders

benserazide has been researched along with Psychotic Disorders in 2 studies

Benserazide: An inhibitor of DOPA DECARBOXYLASE that does not enter the central nervous system. It is often given with LEVODOPA in the treatment of parkinsonism to prevent the conversion of levodopa to dopamine in the periphery, thereby increasing the amount that reaches the central nervous system and reducing the required dose. It has no antiparkinson actions when given alone.
benserazide : A carbohydrazide that results from the formal condensation of the carboxy group of DL-serine with the primary amino group of 4-(hydrazinylmethyl)benzene-1,2,3-triol. An aromatic-L-amino-acid decarboxylase inhibitor (DOPA decarboxylase inhibitor) that does not enter the central nervous system, it is used as its hydrochloride salt as an adjunct to levodopa in the treatment of parkinsonism. By preventing the conversion of levodopa to dopamine in the periphery, it causes an increase in the amount of levodopa reaching the central nervous system and so reduces the required dose. Benserazide has no antiparkinson actions when given alone.

Psychotic Disorders: Disorders in which there is a loss of ego boundaries or a gross impairment in reality testing with delusions or prominent hallucinations. (From DSM-IV, 1994)

Research Excerpts

ExcerptRelevanceReference
"Seven patients with idiopathic Parkinson's disease, aged 62 to 76 years, average duration of the disease approximately eleven years, suffering from severe hallucinosis and paranoid delusions of different degree, in whom conventional therapeutic strategies (administration of benzodiazepines and mild neuroleptics) had no antipsychotic effect, received clozapine, a non-classical highly potent neuroleptic, while blood count was strictly monitored."1.29Therapeutic effect of clozapine in psychotic decompensation in idiopathic Parkinson's disease. ( Helscher, RJ; Pinter, MM, 1993)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19901 (50.00)18.7374
1990's1 (50.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Pinter, MM1
Helscher, RJ1
Hardie, RJ1
Lees, AJ1

Other Studies

2 other studies available for benserazide and Psychotic Disorders

ArticleYear
Therapeutic effect of clozapine in psychotic decompensation in idiopathic Parkinson's disease.
    Journal of neural transmission. Parkinson's disease and dementia section, 1993, Volume: 5, Issue:2

    Topics: Aged; Benserazide; Blood Cell Count; Clozapine; Female; Hallucinations; Humans; Levodopa; Male; Midd

1993
Neuroleptic-induced Parkinson's syndrome: clinical features and results of treatment with levodopa.
    Journal of neurology, neurosurgery, and psychiatry, 1988, Volume: 51, Issue:6

    Topics: Adult; Aged; Antipsychotic Agents; Benserazide; Drug Therapy, Combination; Female; Humans; Levodopa;

1988